comparemela.com

Latest Breaking News On - European atherosclerosis society - Page 3 : comparemela.com

Oral PCSK9 Inhibitor Demonstrated Significant LDL-C Reduction on Top of Statin in Phase I Trial Presented at EAS Congress

Oral PCSK9 Inhibitor Demonstrated Significant LDL-C Reduction on Top of Statin in Phase I Trial Presented at EAS Congress
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.

France
Cambridge
Cambridgeshire
United-kingdom
Sharon-barr
Coll-cardiol
Astrazeneca
European-atherosclerosis-society
European-atherosclerosis-society-congress
Executive-vice-president
United-kingdom-based-astrazeneca
Different-doses

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

LA JOLLA, Calif., May 28, 2024 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the Standard Market of the Tokyo Stock Exchange , today announced that.

Tokyo
Japan
Kazuko-matsuda
Huicheng-qi
Davidh-crean
Nasdaq
Medicinova-inc
Juntendo-university
European-atherosclerosis-society
Exchange-commission
Standard-market
Tokyo-stock-exchange

Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia

- Plozasiran significantly lowered triglyceride levels with commensurate reductions in APOC3, non-HDL-C, and remnant cholesterol - Data presented at European Atherosclerosis Society 92nd Congress.

Daniel-gaudet
Coll-cardiol
Gugliucciaj-clin
Robert-rosenson
Christiem-ballantyne
Baylor-college-of-medicine
Nasdaq
Arrowhead-pharmaceuticals-inc
Exchange-commission
Linkedin
European-atherosclerosis-society
Arrowhead-pharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.